Next Article in Journal
Chemical Profiling, Anticholinesterase, Antioxidant, and Antibacterial Potential of the Essential Oil from Myrcianthes discolor (Kunth) McVaugh, an Aromatic Tree from Southern Ecuador
Next Article in Special Issue
From Gene to Transcript and Peptide: A Deep Overview on Non-Specific Lipid Transfer Proteins (nsLTPs)
Previous Article in Journal
The Antibacterial and Antifungal Capacity of Eight Commercially Available Types of Mouthwash against Oral Microorganisms: An In Vitro Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 4
10.3390/antibiotics12040676
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antimicrobial and Antibiofilm Effect of Bacteriocin-Producing Pediococcus inopinatus K35 Isolated from Kimchi against Multidrug-Resistant Pseudomonas aeruginosa

by
Eun-Ji Yi
and
Ae-Jung Kim
*
Department of Alternative Medicine, Kyonggi University, Seoul 03746, Republic of Korea
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(4), 676; https://doi.org/10.3390/antibiotics12040676
Submission received: 5 March 2023 / Revised: 24 March 2023 / Accepted: 28 March 2023 / Published: 30 March 2023
(This article belongs to the Special Issue Alternatives to Antibiotics: Bacteriocins and Antimicrobial Peptides, 2nd Edition)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: Recently, the emergence of multidrug-resistant bacteria due to the misuse of antibiotics has attracted attention as a global public health problem. Many studies have found that fermented foods are good sources of probiotics that are beneficial to the human immune system. Therefore, in this study, we tried to find a substance for the safe alternative treatment of multidrug-resistant bacterial infection in kimchi, a traditional fermented food from Korea. Method: Antimicrobial activity and antibiofilm activity were assessed against multidrug-resistant (MDR) Pseudomonas aeruginosa using cell-free supernatants of lactic acid bacteria (LAB) isolated from kimchi. Then, UPLC-QTOF-MS analysis was performed to detect the substances responsible for the antimicrobial effect. Results: The cell-free supernatant (CFS) of strain K35 isolated from kimchi effectively inhibited the growth of MDR P. aeruginosa. Similarly, CFS from strain K35 combined with P. aeruginosa co-cultures produced significant inhibition of biofilm formation upon testing. On the basis of 16s rRNA gene sequence similarity, strain K35 was identified as Pediococcus inopinatus. As a result of UPLC-QTOF-MS analysis of the CFS of P. inopinatus K35, curacin A and pediocin A were detected. Conclusion: As a result of this study, it was confirmed that P. inopinatus isolated from kimchi significantly reduced MDR P. aeruginosa growth and biofilm formation. Therefore, kimchi may emerge as a potential source of bacteria able to help manage diseases associated with antibiotic-resistant infections.

1. Introduction

Pseudomonas aeruginosa is a causative pathogenic bacterium ubiquitously known for its metabolic versatility [1]. Infection with P. aeruginosa can range from mild inflammation to lethal systemic disease [2]. Unfortunately, the current guidelines for P. aeruginosa are barely effective due to the low permeability of the signature outer membrane of this Gram-negative bacterium. This property of metabolic flexibility makes it prone to resistance to the current antibiotics on the market [3,4]. Given the seriousness of P. aeruginosa infections and the limited antimicrobial arsenal available to treat them, new antimicrobials with distinct mechanisms of action are desperately needed [5].
Recently, Shokri et al. reported a mechanism related to biofilm formation as a cause of resistance in P. aeruginosa, revealing that 76 (or 95%) of the studied P. aeruginosa strains produced biofilms as a defensive mechanism against antibiotics [6]. Hence, the structure of biofilms may prevent antimicrobial drugs from penetrating the bacterium, as some charged inhibitors can bind to the oppositely charged polymers of the biofilm matrix [7,8]. Several pathways are responsible for the resistance provided by biofilms, but the most prevalently known are stated in Figure 1.
To address the previously mentioned issue of controlling multidrug-resistant (MDR) P. aeruginosa biofilms, widely used probiotic lactic acid bacteria (LAB) such as Enterococcus, Streptococcus, Bifidobacterium, and Lactobacillus species assist in the treatment and control of gut microbiota and have been considered safe choices for the treatment of immune-related diseases such as atopic disease [9]. Various previous studies have indicated that an antibiofilm effect against P. aeruginosa strains can be achieved using LAB metabolites (Table 1). As probiotics, LAB must be able to tolerate pancreatic digestive enzymes, bile, and acids, and eventually to adhere to and function within the intestinal epithelial tissue of the colon [10]. Hence, LAB strains could be a safe option in light of the positive effects associated with specific species or genus strains [11].
Bacteriocins are a group of antimicrobial peptides produced by bacteria that have been studied for their potential therapeutic applications. Bacteriocins in LAB are classified into four groups based on their structural and functional properties. These include lantibiotics, which are modified bacteriocins (class I); non-lantibiotics, which are heat-stable and unmodified (class II); a group of large heat-labile bacteriocins (class III); and class IV, which often includes molecules that are intricate and contain lipid and carbohydrate components. Recent studies have focused more on the potential of class II bacteriocins as novel therapeutic agents [16].
Along the various sources of LAB strains listed in Table 1, the Korean traditional food kimchi is known for the use of LAB as its starter organisms [1]. In previous studies, kimchi-derived LAB were shown to have antimicrobial [3], anti-adipogenic [4], and antioxidant [3,5] effects, making kimchi a potential source of LAB for our study on MDR P. aeruginosa.
Pediococcus inopinatus is a Gram-positive lactic acid bacterial species belonging to the genus Pediococcus and the family Lactobacillaceae, which can exist naturally in plants and fruits and is frequently connected to breweries or other settings in which alcoholic beverages are made [12], including wine [13]. The Pediococcus genus consists of several species, including P. acidilactici, P. pentosaceus, P. damnosus, P. parvulus, P. inopinatus, P. halophilus, P. dextrinicus, and P. urinaeequi [17]. Members of the genus Pediococcus are facultative anaerobes, non-motile, and non-spore-forming. The antimicrobial properties of Pediococcus species, particularly their bacteriocins, have been extensively studied for their potential use in food preservation and as therapeutic agents [16]. Furthermore, the presence of Pediococcus species in fermented foods and beverages highlights their importance in promoting gut health and overall wellbeing, since LAB are famous for being safe and are often used as dairy product starters. Therefore, understanding the properties and applications of the genus Pediococcus could provide new avenues for developing novel therapies and improving food safety, especially in terms of antibiotic-resistant bacteria like P. aeruginosa. P. inopinatus was shown to have an anti-allergy effect when used to produce lactobacillus-fermented soybean milk curd. The in vivo study by Kang et al. showned that P. inopinatus-fermented soy curd had much better anti-allergy properties than soy milk alone for atopic dermatitis treatment [14]. While few studies have been conducted on this LAB strain, it could be a potential option for MDR P. aeruginosa studies.
In this study, we isolated LAB, which are known to have beneficial effects on the human immune system, from traditional fermented foods and evaluated their potential as a safe alternative treatment for multidrug-resistant bacterial infections.

2. Results

2.1. Isolation of Antimicrobial LAB from Kimchi

Strains were isolated from kimchi using the color-changing characteristic of bromocresol purple (BCP), which changes from purple to yellow when the pH is lowered by LAB. In this study, 40 strains that formed yellow rings around colonies on BCP agar (Eiken Chemical Co., Ltd., Tokyo, Japan) plates were selected and used for antimicrobial screening. As a result of the antimicrobial screening of the 40 selected strains, according to the disc diffusion assay, strain K35 showed antimicrobial activity against P. aeruginosa and was selected. The zones of inhibition of antimicrobial activity were 17.5 ± 0.87, 17.33 ± 1.26, and 18.5 ± 0.50 mm against P. aeruginosa KCTC 2513, P. aeruginosa CCARM 0223, and P. aeruginosa CCARM 0224, respectively (Figure 2 and Table 2), and the minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) values were 2.5 and 5 mg/mL against P. aeruginosa KCTC 2513, P. aeruginosa CCARM 0223, and P. aeruginosa CCARM 0224 (Table 3).

2.2. Identification of Strain K35

Phylogenetic analysis was conducted using the 16s rRNA gene. The sequence similarity of strain K35 indicated that its closest relative was Pediococcus inopinatus DSM 20285T (99.79%). This relationship between strain K35 and other members of the genus Pediococcus was also evident in the phylogenetic tree (Figure 3). Biochemical and cultural characteristics were analyzed using Pediococcus inopinatus DSM 20285T, which had the highest similarity according to the phylogenetic analysis, as a comparison strain (Table 4). In the growth temperature test, both strains were able to grow at 25 to 45 °C, and the most suitable temperature was 30 °C. In API 50CH tests, both strains were positive for acid production from D-galactose, D-glucose, D-fructose, D-mannose, N-acetylglucosamine, amygdalin, esculin ferric citrate, salicin, D-cellobiose, D-maltose, D-trehalose, and gentiobiose, while both strains were negative for acid production from glycerol, erythritol, D-arabinose, L-arabinose, D-ribose, L-xylose, D-xylose, D-adonitol, methyl-β-D-xyopyranoside, L-sorbose, L-rhamnose, dulcitol, inositol, D-mannitol, D-sorbitol, methyl-α-D-glucopyranoside, arbutin, D-lactose, D-melibiose, D-saccharose, inulin, D-melezitose, D-raffinose, amidon, glycogen, xylitol, D-lyxose, D-tagatose, D-fucose, L-fucose, D-arabitol, L-arabitol, potassium gluconate, potassium 2-ketogluconate, and potassium 5-ketogluconate.

2.3. Biofilm Formation Inhibitory Activity

The results of the test of biofilm formation inhibitory effect against P. aeruginosa are shown in Figure 4. In the control group, it was shown that biofilm formation increased in a concentration-dependent manner for P. aeruginosa KCTC 2513 and P. aeruginosa CCARM 0224, but for P. aeruginosa CCARM 0223, the change in biofilm amount according to the concentration was not significant. In the K35 treatment group, evaporated CFS did not affect the biofilm formation of P. aeruginosa strains below the MIC concentration, but biofilm formation was significantly inhibited at concentrations above the MIC. It is assumed that the MRS broth (Difco, Detroit, MI, USA) contained in the evaporated CFS of K35 promoted the growth of P. aeruginosa, but at concentrations above the MIC, both growth and biofilm formation were inhibited by the metabolites of K35.

2.4. Observation of the Morphological Changes of Bacterial Cells

The morphological changes of P. aeruginosa KCTC 2513, P. aeruginosa CCARM 0223, and P. aeruginosa CCARM 0224 following treatment with the MBC of CFS from K35 were visualized using scanning electron microscopy (SEM) (Figure 5). Cell surface damage and shortened cell length were observed in the treatment group compared to the control group. In particular, in P. aeruginosa CCARM 0224, evaporated CFS treatment resulted in complete deterioration and cell debris was observed.

2.5. Detection of Substances with Antimicrobial and Anti-Biofilm-Formation Effects

The total ion chromatogram (TIC) and the UV chromatograms of the K35 culture broth are shown in Figure 6. The tentative identification of compounds was performed using Waters software (UNIFI v1.8.1) and an online database (ChemSpider). Compound identification was based on molecular ion mass and fragmentation pattern, and, as a result, curacin A and pediocin A, known as antimicrobial compounds, were tentatively identified in K35. Table 5 shows the elution time, molecular formula, molecular weight, and mass error of the tentatively identified compounds.

3. Discussion

In this study, we attempted to demonstrate that the CFS of P. inopinatus K35 isolated from kimchi has antimicrobial activity and anti-biofilm-formation activity against MDR P. aeruginosa. Recently, as the number of antibiotic-resistant pathogens has greatly increased, the need for research to find new alternative treatments to replace existing antibiotic treatments without serious side effects or toxicity is emerging [18,19]. For this reason, studies on the possible application of LAB metabolites that are effective for the inhibition of P. aeruginosa infection are increasing [6,12,13,14,15].
Several studies have reported the anti-allergic and antimicrobial activity of P. inopinatus [20], and this bacterium has also been shown to inhibit the growth of Escherichia coli, Helicobacter pylori, Listeria monocytogenes, and Staphylococcus aureus [21]. However, data on resistant strains have still not been reported.
According to information provided by the National Research Institute of Korea, P. aeruginosa CCARM 0223 and P. aeruginosa CCARM 0224 strains are resistant to ampicillin, cephalothin, gentamicin, and norfloxacin. In this study, the CFS of P. inopinatus K35 significantly reduced the growth and biofilm formation of P. aeruginosa CCARM 0223 and P. aeruginosa CCARM 0224, which complements the other reports on the antibiofilm effect of LAB that were summarized in Table 1.
Previous studies have reported that antibiotic-resistant strains have the tendency to display enhanced biofilm formation, making it more difficult for antibiotics to penetrate [15]. This biofilm strengthening is consistent with the results of this study, in which the antibiotic-resistant strains P. aeruginosa CCARM 0223 and P. aeruginosa CCARM0224 produced more biofilm than the normal strain P. aeruginosa KCTC 2513 (Figure 4).
The results of our study confirm that even in the face of the strong biofilm formation ability exhibited by antibiotic-resistant bacteria, the cell-free supernatant of K35 can effectively inhibit biofilm formation in MDR P. aeruginosa strains at concentrations of 2.5 mg/mL or higher, as shown in Figure 4. Therefore, these findings suggest that the lactic acid bacteria isolated in this study have the potential to serve as a viable alternative for inhibition of antibiotic-resistant bacteria.
A recent research work stated that antibiotic-resistant strains were observed to have greater cell elongation than normal bacteria [15]. Another study reported that antibiotics such as erythromycin and clarithromycin inhibit the protein synthesis of P. aeruginosa and eventually result in the loss of cell viability [22]. The shrinkage of the P. aeruginosa cells in the treated samples in our work can be attributed to the possible ability of the CFS of K35 to inhibit protein synthesis (Figure 5).
Based on previous findings that antibiotics inhibit pathogens by interfering with the normal cycle of maintenance of cell integrity and by causing cell shrinkage and loss of cell viability [23,24], it is assumed that the CFS of P. inopinatus K35 effectively penetrates the cell wall of P. aeruginosa, interferes with cell growth and normal cell activity, and ultimately inhibits biofilm formation. The efficacy of P. inopinatus K35 was the strongest against P. aeruginosa CCARM 0224, in which it was shown to lead to complete deterioration.
In the context of lactic acid bacteria from food, antimicrobial activity is generally attributed to the presence of organic acids, hydrogen peroxide, or bacteriocins [25,26]. To determine the origin of the antimicrobial activity displayed by the studied P. inopinatus K35, we employed UPLC-TOF-MS analysis. In the chromatography results, curacin A and pediocin A were tentatively identified in P. inopinatus K35 cultured broth.
While curacin A has demonstrated potent antiproliferative and antimitotic effects against human cancer cells [27], its effectiveness as an antimicrobial agent against MDR P. aeruginosa remains to be determined. The differences between prokaryotic (such as P. aeruginosa) and eukaryotic (such as human cancer) cells extend beyond merely their structures; the membrane composition and genetic material also differ significantly [28]. While eukaryotes have a membrane-bound nucleus and other membrane-bound organelles, prokaryotes lack these. Hence, further research is essential to evaluate the potential and to clarify the detailed mechanism of curacin A as an antimicrobial agent against pathogenic bacteria in general and specifically against MDR P. aeruginosa. Pediocin A, on the other hand, is mainly found in Pediococcus spp. and is known to inhibit pathogens such as Bacillus cereus and Listeria monocytogenes effectively [25,26]. These two small antimicrobial peptides, classified as class II bacteriocins, have the potential to be highly specific in their targeting and have a lower likelihood of causing the development of resistance compared to traditional antibiotics [29]. Therefore, these findings suggest that the inhibition of growth and biofilm formation of P. aeruginosa by P. inopinatus K35 may be due to curacin A and pediocin A, representing a promising step toward the development of new and effective treatments for this difficult-to-treat infection. However, further research is needed to understand their mechanisms of action and to evaluate their efficacy and safety in clinical settings.

4. Conclusions

In this study, we isolated P. inopinatus K35 from kimchi, confirmed its antimicrobial activity, and confirmed that this strain effectively inhibits the growth and biofilm formation of three P. aeruginosa strains. In addition, through metabolomic analysis, P. inopinatus K35 was tentatively shown to produce curacin A and pediocin A, and it is suggested that it exerts antibacterial activity against multidrug-resistant bacteria through the production of these bacteriocins. These findings indicate that the lactic acid bacterium K35 isolated from kimchi presents the potential to be developed as an alternative to antibiotics to treat infections caused by P. aeruginosa. It is also suggested that kimchi can be a good source for the isolation of useful microorganisms with antimicrobial ability against multidrug-resistant bacteria.

5. Materials and Methods

5.1. Isolation and Identification of LAB from Kimchi

Kimchi soup was serially diluted in 0.85% (w/v) saline solution to a concentration of 10−6 to 10−9, and was spread onto BCP agar. The plates were then incubated for 2 days at 30 °C. Single colonies that displayed yellow rings around them on BCP plates were transferred to MRS agar plates and routinely cultured on MRS agar and in MRS broth at 30 °C.
To identify the homological strains of the isolates, the 16s rRNA sequence technique with primers 1492R (5′ TACGGYTACCTTGTTACGACTT 3′) and 27F (5′ AGAGTTTGATCCTGGCTCAG 3′) was used. Then, the EzBioCloud database (https://www.ezbiocloud.net/identify, accessed on 15 November 2022) was used to analyze the 16s rRNA sequences. A phylogenetic tree was reconstructed using the neighbor-joining method and the maximum-parsimony method in the MEGA X program with bootstrap values based on 1000 replications [30,31]. For biochemical analysis, a carbohydrate fermentation test was performed using an analytical profile index (API) 50 CH kit (BioMérieux, Marcy l’Etoile, France) [32].

5.2. Bacterial Strains and Growth Conditions

P. aeruginosa KCTC 2513, P. aeruginosa CCARM 0223, and P. aeruginosa CCARM 0224 were purchased from the Korean Collection for Type Cultures (KCTC). P. aeruginosa strains were cultured in nutrient broth (NB; Difco, Detroit, MI, USA) agar under aerobic conditions at 30 °C. Then, the selected LAB was grown in MRS broth for 48 h at 30 °C to produce a mass amount of metabolites. Culture medium was then centrifuged for 10 min at 12,000 rpm, and the supernatant was filtered using a 0.22 μm membrane filter. Subsequently, the filtrates were used directly as samples for antimicrobial activity screening, and filtrates concentrated using a centrifugal evaporator (EYELA, Tokyo, Japan) at 45 °C were utilized for further antimicrobial and antibiofilm tests.

5.3. Disc Diffusion Assay

LAB with antimicrobial properties were identified using the standard disc diffusion approach following the method of Zaidan et al. [33]. First, 100 µL of filtered supernatant was applied to sterile filter paper discs (8 mm diameter, Whatman No. 1), then the discs were placed on Mueller–Hinton agar (MHA; Difco, Detroit, MI, USA) plates spread with pathogen indicators (1 × 106 UFC/mL) and incubated at 30 °C for 24 h. The antimicrobial effects of LAB were analyzed by measuring the diameter of the inhibitory zone in millimeters using calipers [34].

5.4. Broth Microdilution Method

The broth microdilution method described in the Clinical and Laboratory Standards Institute guidelines was utilized to confirm the MIC and MBC of the selected LAB. A 96-well microtiter plate (Thermo Fisher Scientific, Waltham, MA, USA) was used to inoculate serially diluted evaporated CFS of the selected LAB. To each well containing 100 μL of serially diluted evaporated CFS, 100 μL of P. aeruginosa strains in NB (1 × 106 CFU/mL) was added, and the plates were incubated at 30 °C for 24 h. Then, the optical density (OD) was measured at 595 nm using a microplate reader (Molecular Devices, San Francisco, CA, USA), and the concentration showing an OD of 20% or less compared to the control group was set as the MIC. Subsequently, a portion of each well was streaked onto a NB agar plate using a 1 uL inoculation loop. The plates were incubated at 37 °C for 24 h and the number of colonies was observed. The lowest concentration without colony growth on the NB agar plates was recorded as the MBC.

5.5. Biofilm Formation Inhibition Assay

To determine whether treatment of evaporated CFS reduced the amount of biofilm, 100 μL each of the diluted P. aeruginosa strains (1 × 106 CFU/mL) and different concentrations of CFS-K35 (0, 0.31, 0.63, 1.25, 2.5 and 5 mg/mL) were added into 96-well microtiter plates and incubated for 24 h at 37 °C without shaking. After incubation, the solution was discarded, and each well was washed with phosphate-buffered saline (PBS) twice. Subsequently, 100 µL of 0.01% crystal violet solution (in 0.1% acetic acid and 95% ethanol) was added to stain each well for 15 min, followed by rinsing twice with PBS to remove non-specific staining and air drying at room temperature. Fixed crystal violet was released using 33% acetic acid, and then the biofilm formation inhibition was evaluated by measuring OD at 595 nm using a microplate reader. Evaporated MRS broth was used as a control during the biofilm formation test.

5.6. Scanning Electron Microscopy (SEM) of Bacteria

Dilutions of 1 × 107 CFU/mL of P. aeruginosa were reacted with the MBC of evaporated CFS at 37 °C for 24 h. P. aeruginosa samples were then fixed for 3 h at 4 °C with 2.5% glutaraldehyde in PBS. The fixed samples were dehydrated using ethanol solutions with progressively higher concentrations (30%, 50%, 70%, 80%, 90%, and 100%). After dehydration, the bacteria were dried overnight by adding 100 μL of hexamethyldisilazane (Sigma Aldrich, St. Louis, MO, USA). Carbon tape was attached to the stub and dried samples were mounted on it. Then, plasma was generated on the surface of the non-conductive sample to create a metal film. Bacteria were imaged using a SU8010 scanning electron microscope (Hitachi, Tokyo, Japan).

5.7. UPLC-QTOF-MS Analysis

Further analysis was conducted using an UPLC (ACQUITY UPLC I-Class System, Waters, Milford, MA, USA) connected to a quadrupole time-of-flight (Q-TOF) mass spectrometer detector (Xevo G2–XS, Waters, Milford, MA, USA). The mass spectrometer was operated in negative-ion electrospray mode with a mobility-enabled non-targeted HDMSE scan method, with a range of 50–2000 Da and a 0.1 s scan time. In this investigation, 0.1% formic acid in water and acetonitrile were used as the mobile phases A and B, respectively, to produce chromatographic separation at a flow rate of 0.35 mL/min. The elution conditions were as follows: 0–1 min, 0–1 min, 0% B; 1–4 min, 0–55% B; 4–14 min, 55–90% B; 14–14.5 min, 90–99% B; 14.5–17 min, 99% B; 17–17.1 min 99–0% B; 17.1–20 min 0% B. Detection wavelengths of 254 and 320 nm were used. The energies of the MS low and high collisions were 6 and 20 to 60 eV, respectively. The drying gas utilized was nitrogen. The cone gas flow was kept at 50 L/h, while the desolvation gas flow was 800 L/h. The source temperature was 100 °C, whereas the desolvation temperature was 350 °C. The capillary and sampling cones were 1.8 KV and 30 V. A 2.0 KV reference capillary was used. Data were gathered and processed using UNIFI v1.8.1 software.

5.8. Statistical Analysis

GraphPad Prism 9 (GraphPad Software Inc., La Jolla, CA, USA) was utilized to analyze the one-way ANOVA and two-way ANOVA. The data in this study were collected in three replications each and are presented as mean ± standard deviation. p < 0.05 was regarded as a significant value in all statistical analyses.

Author Contributions

Conceptualization, E.-J.Y.; methodology, E.-J.Y.; software, E.-J.Y.; validation, A.-J.K.; formal analysis, E.-J.Y.; investigation, E.-J.Y.; resources, E.-J.Y.; data curation, E.-J.Y.; writing—original draft preparation, E.-J.Y.; writing—review and editing, E.-J.Y. and A.-J.K.; visualization, E.-J.Y.; supervision, A.-J.K.; project administration, E.-J.Y. and A.-J.K.; funding acquisition, E.-J.Y. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in this paper.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Strateva, T.; Mitov, I. Contribution of an arsenal of virulence factors to pathogenesis of Pseudomonas aeruginosa infections. Ann. Microbiol. 2011, 61, 717–732. [Google Scholar] [CrossRef]
  2. Wu, D.C.; Chan, W.W.; Metelitsa, A.I.; Fiorillo, L.; Lin, A.N. Pseudomonas skin infection: Clinical features, epidemiology, and management. Am. J. Clin. Dermatol. 2011, 12, 157–169. [Google Scholar] [CrossRef]
  3. Breidenstein, E.B.; de la Fuente-Núñez, C.; Hancock, R.E. Pseudomonas aeruginosa: All roads lead to resistance. Trends Microbiol. 2011, 19, 419–426. [Google Scholar] [CrossRef] [PubMed]
  4. Henrichfreise, B.; Wiegand, I.; Pfister, W.; Wiedemann, B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother. 2007, 51, 4062–4070. [Google Scholar] [CrossRef] [Green Version]
  5. Gellatly, S.L.; Hancock, R.E. Pseudomonas aeruginosa: New insights into pathogenesis and host defenses. Pathog. Dis. 2013, 67, 159–173. [Google Scholar] [CrossRef] [Green Version]
  6. Shokri, D.; Khorasgani, M.R.; Mohkam, M.; Fatemi, S.M.; Ghasemi, Y.; Taheri-Kafrani, A. The inhibition effect of lactobacilli against growth and biofilm formation of Pseudomonas aeruginosa. Probiotics Antimicrob. Proteins 2018, 10, 34–42. [Google Scholar] [CrossRef] [PubMed]
  7. Marsh, P.D. Dental plaque as a biofilm: The significance of pH in health and caries. Compend. Contin. Educ. Dent. 2009, 30, 76–78, 80, 83. [Google Scholar]
  8. Taraszkiewicz, A.; Fila, G.; Grinholc, M.; Nakonieczna, J. Innovative strategies to overcome biofilm resistance. BioMed Res. Int. 2013, 2013, 150653. [Google Scholar] [CrossRef] [Green Version]
  9. Bajaj, B.K.; Claes, I.J.; Lebeer, S. Functional mechanisms of probiotics. J. Microbiol. Biotechnol. Food Sci. 2021, 2021, 321–327. [Google Scholar]
  10. Vemuri, R.; Shinde, T.; Shastri, M.D.; Perera, A.P.; Tristram, S.; Martoni, C.J.; Gundamaraju, R.; Ahuja, K.D.; Ball, M.; Eri, R. A human origin strain Lactobacillus acidophilus DDS-1 exhibits superior in vitro probiotic efficacy in comparison to plant or dairy origin probiotics. Int. J. Med. Sci. 2018, 15, 840. [Google Scholar] [CrossRef] [Green Version]
  11. Kumar Bajaj, B.; Andrabi, T.; JJ Claes, I.; Lebeer, S. Bioprospecting for functionally-proficient potential probiotics. Curr. Nutr. Food Sci. 2014, 10, 251–263. [Google Scholar] [CrossRef]
  12. Alexandre, Y.; Le Berre, R.; Barbier, G.; Le Blay, G. Screening of Lactobacillus spp. for the prevention of Pseudomonas aeruginosa pulmonary infections. BMC Microbiol. 2014, 14, 107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Singh, V.; Ganger, S.; Patil, S. Characterization of Lactobacillus brevis with Potential Probiotic Properties and Biofilm Inhibition against Pseudomonas aeruginosa. Proceedings 2020, 66, 14. [Google Scholar]
  14. Valdez, J.; Peral, M.; Rachid, M.; Santana, M.; Perdigon, G. Interference of Lactobacillus plantarum with Pseudomonas aeruginosa in vitro and in infected burns: The potential use of probiotics in wound treatment. Clin. Microbiol. Infect. 2005, 11, 472–479. [Google Scholar] [CrossRef] [Green Version]
  15. Wilson, R.M.; Walker, J.M.; Yin, K. Different Concentrations of Lactobacillus acidophilus cell free filtrate have differing anti-biofilm and immunomodulatory effects. Front. Cell. Infect. Microbiol. 2021, 11, 864. [Google Scholar] [CrossRef]
  16. Papagianni, M.; Anastasiadou, S. Pediocins: The bacteriocins of Pediococci. Sources, production, properties and applications. Microb. Cell Factories 2009, 8, 3. [Google Scholar] [CrossRef] [Green Version]
  17. Garvie, E. Genus Pediococcus Claussen 1903, 68. Bergey’s Man. Syst. Bacteriol. 1986, 2, 1075–1079. [Google Scholar]
  18. Reynolds, D.; Kollef, M. The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: An update. Drugs 2021, 81, 2117–2131. [Google Scholar] [CrossRef]
  19. Smith, A.W. Biofilms and antibiotic therapy: Is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv. Drug Deliv. Rev. 2005, 57, 1539–1550. [Google Scholar] [CrossRef]
  20. Kang, M.-S.; Lee, Y.-G.; Kim, H.-S.; Chung, H.-S.; Hwang, D.-Y.; Kim, D.-S. Therapeutic Antiallergy Effect of Fermented Soy Curd by Pediococcus inopinatus Y2. J. Life Sci. 2019, 29, 478–483. [Google Scholar]
  21. Lim, S.-J.; Bae, E.-Y.; Seol, M.-K.; Cho, Y.-j.; Jung, H.-Y.; Kim, B.-O. Change in Lactobacillus brevis GS1022 and Pediococcus inopinatus GS316 in Gajami Sikhae Fermentation. J. Life Sci. 2020, 30, 491–500. [Google Scholar]
  22. Tateda, K.; Ishii, Y.; Matsumoto, T.; Kobayashi, T.; Miyazaki, S.; Yamaguchi, K. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: Suppression of virulence factors and stress response. J. Infect. Chemother. 2000, 6, 1–7. [Google Scholar] [CrossRef] [PubMed]
  23. Benbrook, D.M.; Miller, R.V. Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1986, 29, 1–6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Wang, L.; Ye, C.; Guo, L.; Chen, C.; Kong, X.; Chen, Y.; Shu, L.; Wang, P.; Yu, X.; Fang, J. Assessment of the UV/Chlorine Process in the Disinfection of Pseudomonas aeruginosa: Efficiency and Mechanism. Environ. Sci. Technol. 2021, 55, 9221–9230. [Google Scholar] [CrossRef] [PubMed]
  25. Khorshidian, N.; Khanniri, E.; Mohammadi, M.; Mortazavian, A.M.; Yousefi, M. Antibacterial activity of pediocin and pediocin-producing bacteria against Listeria monocytogenes in meat products. Front. Microbiol. 2021, 12, 709959. [Google Scholar] [CrossRef] [PubMed]
  26. Piva, A.; Headon, D.R. Pediocin A, a bacteriocin produced by Pediococcus pentosaceus FBB61. Microbiology 1994, 140, 697–702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Rath, C.M.; Scaglione, J.B.; Kittendorf, J.D.; Sherman, D.H. NRPS/PKS hybrid enzymes and their natural products. Chem. Mol. Sci. Chem. Eng. 2010, 1, 453–492. [Google Scholar]
  28. Vellai, T.; Vida, G. The origin of eukaryotes: The difference between prokaryotic and eukaryotic cells. Proc. R. Soc. London. Ser. B Biol. Sci. 1999, 266, 1571–1577. [Google Scholar] [CrossRef] [Green Version]
  29. Mills, S.; Ross, R.P.; Hill, C. Bacteriocins and bacteriophage; a narrow-minded approach to food and gut microbiology. FEMS Microbiol. Rev. 2017, 41, S129–S153. [Google Scholar] [CrossRef]
  30. Fitch, W.M. Toward defining the course of evolution: Minimum change for a specific tree topology. Syst. Biol. 1971, 20, 406–416. [Google Scholar] [CrossRef]
  31. Saitou, N.; Nei, M. The neighbor-joining method: A new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 1987, 4, 406–425. [Google Scholar] [PubMed]
  32. Abdelbasset, M.; Djamila, K. Antimicrobial activity of autochthonous lactic acid bacteria isolated from Algerian traditional fermented milk “Raïb”. Afr. J. Biotechnol. 2008, 7, 2908–2914. [Google Scholar]
  33. Zaidan, M.; Noor Rain, A.; Badrul, A.; Adlin, A.; Norazah, A.; Zakiah, I. In vitro screening of five local medicinal plants for antibacterial activity using disc diffusion method. Trop. Biomed. 2005, 22, 165–170. [Google Scholar]
  34. Palepou, M.; Johnson, A.; Cookson, B.; Beattie, H.; Charlett, A.; Woodford, N. Evaluation of disc diffusion and Etest for determining the susceptibility of Staphylococcus aureus to mupirocin. J. Antimicrob. Chemother. 1998, 42, 577–583. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Antibiotics 12 00676 g001 550
Figure 1. Mechanisms of P. aeruginosa biofilm-mediated antibiotic resistance.
Figure 1. Mechanisms of P. aeruginosa biofilm-mediated antibiotic resistance.
Antibiotics 12 00676 g001
Antibiotics 12 00676 g002 550
Figure 2. Antimicrobial activity by CFS of P. inopinatus K35 against P. aeruginosa KCTC 2513, CCARM 0223, and CCARM 0224.
Figure 2. Antimicrobial activity by CFS of P. inopinatus K35 against P. aeruginosa KCTC 2513, CCARM 0223, and CCARM 0224.
Antibiotics 12 00676 g002
Antibiotics 12 00676 g003 550
Figure 3. Neighbor-joining phylogenetic tree of strain K35. Bootstrap values (expressed as a percentage of 1000 replications) > 65% are shown at the branch points. Bar, 0.01 substitutions per nucleotide position.
Figure 3. Neighbor-joining phylogenetic tree of strain K35. Bootstrap values (expressed as a percentage of 1000 replications) > 65% are shown at the branch points. Bar, 0.01 substitutions per nucleotide position.
Antibiotics 12 00676 g003
Antibiotics 12 00676 g004 550
Figure 4. Anti-biofilm-formation activities of P. inopinatus K35 against (a) P. aeruginosa KCTC 2513, (b) P. aeruginosa CCARM 0223, and (c) P. aeruginosa CCARM 0224. (d) Representative images of biofilm inhibition by P. inopinatus K35 are shown. Data are presented as mean ± SD of the results from three replicates. ** p ≤ 0.01, *** p ≤ 0.001.
Figure 4. Anti-biofilm-formation activities of P. inopinatus K35 against (a) P. aeruginosa KCTC 2513, (b) P. aeruginosa CCARM 0223, and (c) P. aeruginosa CCARM 0224. (d) Representative images of biofilm inhibition by P. inopinatus K35 are shown. Data are presented as mean ± SD of the results from three replicates. ** p ≤ 0.01, *** p ≤ 0.001.
Antibiotics 12 00676 g004
Antibiotics 12 00676 g005 550
Figure 5. Scanning electron microscopy (SEM) (magnification, 50,000×, bar 1 µm) images of P. aeruginosa. (a) Untreated P. aeruginosa KCTC 2513 cells. (b) Untreated P. aeruginosa CCARM 0223 cells. (c) Untreated P. aeruginosa CCARM 0224 cells. (d) P. aeruginosa KCTC 2513 cells treated with 5 mg/mL of P. inopinatus K35 CFS for 24 h. (e) P. aeruginosa CCARM 0223 cells treated with 5 mg/mL of P. inopinatus K35 CFS for 24 h. (f) P. aeruginosa CCARM 0224 cells treated with 5 mg/mL of P. inopinatus K35 CFS for 24 h.
Figure 5. Scanning electron microscopy (SEM) (magnification, 50,000×, bar 1 µm) images of P. aeruginosa. (a) Untreated P. aeruginosa KCTC 2513 cells. (b) Untreated P. aeruginosa CCARM 0223 cells. (c) Untreated P. aeruginosa CCARM 0224 cells. (d) P. aeruginosa KCTC 2513 cells treated with 5 mg/mL of P. inopinatus K35 CFS for 24 h. (e) P. aeruginosa CCARM 0223 cells treated with 5 mg/mL of P. inopinatus K35 CFS for 24 h. (f) P. aeruginosa CCARM 0224 cells treated with 5 mg/mL of P. inopinatus K35 CFS for 24 h.
Antibiotics 12 00676 g005
Antibiotics 12 00676 g006 550
Figure 6. UPLC-QTOF-MS chromatogram of cell-free supernatant from P. inopinatus K35. (a) Curacin A. (b) Pediocin A.
Figure 6. UPLC-QTOF-MS chromatogram of cell-free supernatant from P. inopinatus K35. (a) Curacin A. (b) Pediocin A.
Antibiotics 12 00676 g006
Table
Table 1. LAB strains known to be effective against P. aeruginosa.
Table 1. LAB strains known to be effective against P. aeruginosa.
No.SourceLAB Strain NameInhibitionCitation
1Oral cavityLimosilactobacillus fermentum ES.A.295%[12]
2Limosilactobacillus fermentum ES.F.11593%
3Limosilactobacillus fermentum ES.A.6a88%
4Limosilactobacillus fermentum ES.A.1a88%
5Milk and yogurtLimosilactobacillus fermentum L1100%[6]
6Limosilactobacillus fermentum L2100%
7Milk, yogurt, buttermilk, idli batterLevilactobacillus brevis SII52.63%[13]
8SauerkrautLactiplantibacillus plantarum ATCC 10241100%[14]
9HumanLactobacillus acidophilus ATCC 4356T99.99%[15]
Table
Table 2. Antimicrobial activity as diameter of inhibition zone of P. inopinatus K35 using disc diffusion assay. Data are presented as mean ± SD of the results from three replicates. * ND, non-detected.
Table 2. Antimicrobial activity as diameter of inhibition zone of P. inopinatus K35 using disc diffusion assay. Data are presented as mean ± SD of the results from three replicates. * ND, non-detected.
StrainZone of Inhibition (mm)
P. aeruginosa KCTC 2513P. aeruginosa CCARM 0223P. aeruginosa CCARM 0224
LAB supernatant (100 µL/disc)
P. inopinatus K3517.5 ± 0.8717.33 ± 1.2618.5 ± 0.50
Antibiotic
Ampicillin (5 mg/disc)20.17 ± 1.0416.67 ± 0.58ND
Gentamicin (2 µg/disc)ND *NDND
Table
Table 3. The minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of CFSs of P. inopinatus K35.
Table 3. The minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) of CFSs of P. inopinatus K35.
StrainMIC (mg/mL)MBC (mg/mL)
P. aeruginosa KCTC 2513≥2.55
P. aeruginosa CCARM 0223≥2.55
P. aeruginosa CCARM 0224≥2.55
Table
Table 4. Biochemical and cultural characteristics of strain K35 and Pediococcus inopinatus DSM 20285T. +, Positive; −, negative; w, weakly positive.
Table 4. Biochemical and cultural characteristics of strain K35 and Pediococcus inopinatus DSM 20285T. +, Positive; −, negative; w, weakly positive.
CharacteristicsK35DSM 20285T
Isolation sourceKimchiBrewery yeast
Growth at
25 °C++
30 °C++
37 °Cww
45 °Cww
Acid produced from:
D-galactose++
D-glucose++
D-fructose++
D-mannose++
Methyl-α-D-mannopyranoside+−
N-acetylglucosamine++
Amygdalinw+
Esculin ferric citrate++
Salicin++
D-cellobiose++
D-maltoseww
D-trehalose++
Gentiobiose++
D-turanose+−
Table
Table 5. Identification of antimicrobial compounds from P. inopinatus K35.
Table 5. Identification of antimicrobial compounds from P. inopinatus K35.
No.CompoundObserved RT (min)FormulaTheoretical Mass (m/z)Observed Mass (m/z)Mass Error (mDa)Adducts
1Curacin A2.61C23H35NOS372.2367372.2344−2.2-H
2Pediocin A3.37C46H68N12O14S1043.46261043.4577−4.9-H
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Yi, E.-J.; Kim, A.-J. Antimicrobial and Antibiofilm Effect of Bacteriocin-Producing Pediococcus inopinatus K35 Isolated from Kimchi against Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics 2023, 12, 676. https://doi.org/10.3390/antibiotics12040676

AMA Style

Yi E-J, Kim A-J. Antimicrobial and Antibiofilm Effect of Bacteriocin-Producing Pediococcus inopinatus K35 Isolated from Kimchi against Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics. 2023; 12(4):676. https://doi.org/10.3390/antibiotics12040676

Chicago/Turabian Style

Yi, Eun-Ji, and Ae-Jung Kim. 2023. "Antimicrobial and Antibiofilm Effect of Bacteriocin-Producing Pediococcus inopinatus K35 Isolated from Kimchi against Multidrug-Resistant Pseudomonas aeruginosa" Antibiotics 12, no. 4: 676. https://doi.org/10.3390/antibiotics12040676

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop